title: Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.
abstract: OBJECTIVE
  To evaluate the performance characteristics of florbetapir F18 positron emission tomography (PET) in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy control subjects (HCs).
  
  
  METHODS
  Florbetapir PET was acquired in 184 subjects (45 AD patients, 60 MCI patients, and 79 HCs) within a multicenter phase 2 study. Amyloid burden was assessed visually and quantitatively, and was classified as positive or negative.
  
  
  RESULTS
  Florbetapir PET was rated visually amyloid positive in 76% of AD patients, 38% of MCI patients, and 14% of HCs. Eighty-four percent of AD patients, 45% of MCI patients, and 23% of HCs were classified as amyloid positive using a quantitative threshold. Amyloid positivity and mean cortical amyloid burden were associated with age and apolipoprotein E ε4 carrier status.
  
  
  CONCLUSIONS
  : The data are consistent with expected rates of amyloid positivity among individuals with clinical diagnoses of AD and MCI, and indicate the potential value of florbetapir F18 PET as an adjunct to clinical diagnosis.
authors: Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: kajohnson@pet.mgh.harvard.edu.
authors: Keith A
authors: KA
authors: Johnson
authors: Reisa A
authors: RA
authors: Sperling
authors: Christopher M
authors: CM
authors: Gidicsin
authors: Jeremy S
authors: JS
authors: Carmasin
authors: Jacqueline E
authors: JE
authors: Maye
authors: Ralph E
authors: RE
authors: Coleman
authors: Eric M
authors: EM
authors: Reiman
authors: Marwan N
authors: MN
authors: Sabbagh
authors: Carl H
authors: CH
authors: Sadowsky
authors: Adam S
authors: AS
authors: Fleisher
authors: P
authors: P
authors: Murali Doraiswamy
authors: Alan P
authors: AP
authors: Carpenter
authors: Christopher M
authors: CM
authors: Clark
authors: Abhinay D
authors: AD
authors: Joshi
authors: Ming
authors: M
authors: Lu
authors: Michel
authors: M
authors: Grundman
authors: Mark A
authors: MA
authors: Mintun
authors: Michel J
authors: MJ
authors: Pontecorvo
authors: Daniel M
authors: DM
authors: Skovronsky
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000375:Aging; D000544:Alzheimer Disease / Q000000981:diagnostic imaging* / Q000235:genetics; D058227:Amyloidogenic Proteins / Q000378:metabolism*; D000814:Aniline Compounds; D053327:Apolipoprotein E4 / Q000235:genetics; D060825:Cognitive Dysfunction / Q000000981:diagnostic imaging* / Q000235:genetics; D005260:Female; D005462:Fluorine Radioisotopes; D006801:Humans; D008297:Male; D008609:Mental Status Schedule; D008875:Middle Aged; D049268:Positron-Emission Tomography; D013267:Stilbenes
chemical_list: D058227:Amyloidogenic Proteins; D000814:Aniline Compounds; D053327:Apolipoprotein E4; D005462:Fluorine Radioisotopes; D013267:Stilbenes; C527756:4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
keywords: Alzheimer's disease; Amyloid; Amyvid; Florbetapir; Mesh; PET
references: Ann Neurol. 2009 Apr;65(4):403-13
references: 19296504
references: J Nucl Med. 2009 Nov;50(11):1887-94
references: 19837759
references: J Neuropathol Exp Neurol. 1998 Dec;57(12):1168-74
references: 9862640
references: Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S85-8
references: 9330992
references: J Psychiatr Res. 1982-1983;17(1):37-49
references: 7183759
references: Arch Neurol. 2007 Mar;64(3):431-4
references: 17353389
references: Lancet Neurol. 2010 Apr;9(4):363-72
references: 20189881
references: J Psychiatr Res. 1975 Nov;12(3):189-98
references: 1202204
references: Ann Neurol. 1999 Mar;45(3):358-68
references: 10072051
references: Arch Neurol. 2008 Nov;65(11):1509-17
references: 19001171
references: Acta Neuropathol. 2010 Feb;119(2):221-33
references: 19690877
references: Neurology. 1989 Sep;39(9):1159-65
references: 2771064
references: Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S27-32
references: 9330982
references: J Nucl Med. 2012 Mar;53(3):378-84
references: 22331215
references: Ann Neurol. 2009 May;65(5):557-68
references: 19475670
references: Ann Neurol. 2010 Mar;67(3):353-64
references: 20373347
references: Neurology. 2005 Mar 8;64(5):834-41
references: 15753419
references: Brain. 2008 Jun;131(Pt 6):1630-45
references: 18339640
references: JAMA. 2011 Jan 19;305(3):275-83
references: 21245183
references: Neurobiol Aging. 2010 Aug;31(8):1275-83
references: 20472326
references: J Nucl Med. 2010 Jun;51(6):913-20
references: 20501908
references: Neurology. 2008 Sep 16;71(12):903-10
references: 18794492
references: Lancet Neurol. 2007 Aug;6(8):734-46
references: 17616482
references: Lancet Neurol. 2010 Nov;9(11):1118-27
references: 20934914
references: Neurobiol Aging. 2008 Oct;29(10):1456-65
references: 17499392
references: Brain. 2007 Nov;130(Pt 11):2837-44
references: 17928318
references: Am J Psychiatry. 1984 Nov;141(11):1356-64
references: 6496779
references: South Med J. 1997 Jul;90(7):720-2
references: 9225895
references: Neurology. 2000 Aug 8;55(3):370-6
references: 10932270
references: Brain. 2009 May;132(Pt 5):1355-65
references: 19339253
references: Neurology. 1984 Jul;34(7):939-44
references: 6610841
references: Arch Neurol. 2006 May;63(5):665-72
references: 16682536
references: J Neuropathol Exp Neurol. 2003 Nov;62(11):1087-95
references: 14656067
references: Ann Neurol. 2011 Jun;69(6):1032-42
references: 21437929
references: Neurology. 1993 Nov;43(11):2412-4
references: 8232972
references: Alzheimers Dement. 2011 May;7(3):263-9
references: 21514250
references: Neurobiol Aging. 2010 Apr;31(4):542-8
references: 18619711
references: Brain. 2006 Nov;129(Pt 11):2856-66
references: 16854944
references: Neuron. 2009 Jul 30;63(2):178-88
references: 19640477
references: Arch Neurol. 2007 Mar;64(3):343-9
references: 17210801
references: Neurology. 2009 Sep 8;73(10):754-60
references: 19587325
references: Ann Neurol. 2004 Mar;55(3):306-19
references: 14991808